Akademik Veri Yönetim Sistemi
European Congress of Clinical Microbiology and Infectious Diseases, Paris, Fransa, 18 - 21 Nisan 2020, ss.2732
Background: Diagnosis of lower respiratory tract infections,
hospital-acquired pneumonia (HAP) or community-associated pneumonia (CAP) in
patients remains an important and challenging problem associated with
significant morbidity, mortality, and cost. Syndromic lower respiratory tract
infection panel (Biofire LRTI Panel) may shorten the time to apply the targeted
antimicrobial treatment in patients with pneumonia and provide rapid
application of isolation measures. The aim of this study was to investigate the
impact of Biofire LRTI Panel on targeted antimicrobial therapy and management
of infection control in patients diagnosed with community-acquired pneumonia
(CAP) or early hospital-acquired pneumonia (HAP) whom are planned to be
hospitalized and treated in intensive care unit (ICU). Materials/methods:
Between October 2018 and September 2019, >18 years old patients admitted to
Marmara University Pendik Training and Research Hospital, and planned to be hospitalized
with the diagnosis of CAP or early HAP were chosen. Patients excreted sputa
with <10 squamous epithelial cells, >25 PNL in each high-power field at
microscopic examination were included. Bacterial culture and syndromic lower
respiratory tract infection panel (Film Array LRTI Panel, RUO version, BioFire
Diagnostics, USA) performed simultaneously on sputum samples. Results were
blind evaluated by two infectious diseases specialists for the decison of
treatment change and application of infection control measures. Decision of
antibiotic change, time to optimal antimicrobial change, bacterial culture
result, Biofire LRTI panel result and applied infection control measures were
recorded for each patient. Results: Forty patients were met the inclusion
criteria and evaluated. Biofire LRTI Panel detected at least one pathogen in 31
patients (77.5%), among these, 29 had bacterial, 15 had bacterial and viral,
and 2 had viral pathogens. No pathogen could be detected in 9 patients (22.5%).
Sputum cultures were positive only in 14/40 (35%) patients. Antibiotic change
was decided in 20 patients and infection control measures were applied in 21
patients (Table 1&2). Conclusions: Biofire LRTI Panel provides faster
access to optimal antimicrobial treatment and high rate of antibiotic
de-escalation in patients diagnosed with CAP and early HAP, and also
contributes to the rapid implementation of infection control measures.